Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has announcements × beta-Thalassemia × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 55 Breast Neoplasms 32 Neoplasms 30 Multiple Myeloma 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Recurrence 18 Leukemia, Myeloid, Acute 18 Colorectal Neoplasms 16 Neoplasm Metastasis 15 Lymphoma, Non-Hodgkin 15 Melanoma 14 Leukemia, Lymphocytic, Chronic, B-Cell 14 Leukemia 13 Carcinoma, Renal Cell 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Ovarian Neoplasms 12 Lymphoma, Follicular 12 Myelodysplastic Syndromes 10 Lymphoma, Large B-Cell, Diffuse 10 Lung Neoplasms 10 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Urinary Bladder Neoplasms 9 Hematologic Neoplasms 9 Carcinoma, Hepatocellular 9 Adenocarcinoma 9 Small Cell Lung Carcinoma 8 Prostatic Neoplasms 8 Lymphoma, Mantle-Cell 8 Lymphoma, B-Cell, Marginal Zone 8 Head and Neck Neoplasms 8

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02604433 2023-04-18

BELIEVE

Celgene

Phase 3 Completed

336 enrolled 38 charts 1 FDA

beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡